Schizophrenia is a common psychiatric disorder characterized by positive (eg, delusions and hallucinations) and negative symptoms (eg, anhedonia and asociality). 1 The dysregulation of dopaminergic function in the midbrain is thought to contribute to the symptomatology of schizophrenia. 
mesocortical dopaminergic transmission may explain why some patients, often with prominent negative symptoms, are not responsive to compounds that block dopamine (DA) transmission. [5] [6] [7] It is well have been shown to fine-tune dopaminergic transmission. 8, 9 These compounds may decrease dopaminergic hyperactivity (reducing positive symptoms) and increase dopaminergic hypo-activity (improving negative or cognitive symptoms), while they demonstrate favorable metabolic profile (for review, see reference [10, 11] ).
Dopaminergic neurons in the mesencephalic ventral tegmental area (VTA) project primarily to the frontal cortex and ventral striatum; those in the laterally adjacent substantia nigra pars compacta (SNc) project primarily to the dorsal striatum. [12] [13] [14] The firing rates of these mesocortical and mesostriatal projection neurons are regulated by dopamine autoreceptors and other neurotransmitters, including glutamate, gamma-aminobutyric acid (GABA), and serotonin (5-HT). 15 These projections modulate the responses of target neurons that mediate complex, fundamental brain functions including cognition, reward processes, and locomotion. 16, 17 The atypical antipsychotic cariprazine, a DA D 3 /D 2 receptor partial agonist, is FDA approved for the treatment of patients with schizophrenia and manic or mixed episodes associated with bipolar I disorder. Differentiating properties of cariprazine include its higher affinity and selectivity for D 3 vs D 2 receptors, 18 displaying subnanomolar and 5-fold to 8-fold higher in vitro binding affinity for the former, and its occupancy of a high percentage of both receptor subtypes in vivo at pharmacological and antipsychotic effective doses in both animals 19 and humans. 20 Additionally, cariprazine is a partial agonist with nanomolar affinity for human 5-HT 1A receptors. 18 It has subnanomolar affinity for human 5-HT 2B receptors and nanomolar affinity for human 5-HT 2A receptors, exerting antagonist action at these serotonin receptor subtypes. 18 Cariprazine also binds to other receptors in vitro with moderateto-low affinities; namely, the histamine H 1 , 5-HT 2C , and α 1A -adrenergic receptors. 18 Of note, both 5-HT 1A and 5-HT 2B receptors have been proposed to play role in the antipsychotic-like response in animal models. 21, 22 The efficacy and safety of cariprazine in patients with schizophrenia have been supported by 3 positive, randomized, placebo-controlled, phase II/III clinical studies. [23] [24] [25] Cariprazine has also shown procognitive 26, 27 and antidepressantlike 28 effects in animal behavioral models, suggesting that it may be efficacious in the treatment of the cognitive deficits and negative symptoms of schizophrenia. 29 The objective of this study was to investigate the contribution of D 2 versus D 3 receptors in the mechanism of action of cariprazine, using relatively subtype-selective DA receptor ligands as tools.
Specifically, this study explored the role of these receptors on acute and chronic region-specific effects of cariprazine on mesencephalic dopaminergic neuron firing activity in vivo using extracellular singlecell recordings in anesthetized rats. 
| ME THODS

| Animals
The acute and chronic oral (p.o.) cariprazine studies were performed using male Sprague-Dawley rats (150-175 g at the start of the study;
Taconic Farms, NY). As always used by Univ. of Lyon's group, studies examining the effects of intravenous (i.v.) administration of cariprazine on VTA and SNc neurons were performed using male 
| Surgery
For all experiments, rats were anesthetized with chloral hydrate Design, Cambridge, UK). The detection of bursts within spontaneously active neurons was performed using a Spike 2 script based on the criteria of Grace and Bunney. 31 The beginning of a burst was defined with the occurrence of two spikes within 80 milliseconds, and the ending of a burst was determined as an interspike interval of longer than 160 milliseconds. The firing and bursting activity were quantified relative to baseline, and drug-induced changes in neuronal activities were defined as percent changes from this baseline after the injection of a pharmacologic compound. Dose-response curves were constructed by plotting the firing rates normalized to the mean firing rate of the vehicle over a period of at least 5 minutes against doses. The ED 50 values were calculated for each animal using a sigmoid curve fitting method for firing activity; for bursting activity, the ED 50 values were obtained from pooled, averaged data of each dose.
VTA or SNc neurons were considered dopaminergic if they exhibited the following predetermined characteristics: (i) slow (2.0-9.0 Hz) firing rate, with or without burst firing; (ii) action potentials having biphasic or triphasic waveform with a duration of at least 1.1 ms (measured from spike initiation to the maximal negative phase of the action potential); and (iii) a characteristic, low-pitch sound when monitored through an audio amplifier. 2, 32 At the end of the experiments, animals were deeply anesthetized with a pentobarbital overdose (100 mg/kg), and their brains were removed, snap-frozen in isopentane (Sigma-Aldrich), and stored at −40°C. The location of electrode in the targeted region was determined histologically on serial coronal sections (60 μm) and, as exemplified in Figure 5 , only data obtained from rats with correctly implanted electrodes were included in the results.
| Drugs
Cariprazine (Tocris, Bristol, UK), and L741,626 (Tocris, Bristol, UK) were dissolved in a solution of 10% hydroxypropyl-β-cyclodextrin in distilled water. 
| Data analysis
The oral and i.v. cariprazine data were analyzed using analysis of variance (ANOVA) followed by an appropriate post hoc test that SNc were analyzed using a repeated measures ANOVA followed by Dunnett's post hoc test. The a priori significance level was P < .05.
All summary data are presented as the means ± SEM.
| RE SULTS
| Effects of cariprazine on the number of spontaneously active VTA and SNc dopaminergic neurons
The acute oral administration of 0.3 and 1 mg/kg cariprazine, but not 0.1 mg/kg, significantly increased the number of spontaneously active VTA dopaminergic neurons by 38% and 44% compared with vehicle, respectively (P < .01; Figure 1A ). In contrast, cariprazine did not significantly alter the number of spontaneously active SNc dopaminergic neurons compared with vehicle ( Figure 1A ). Chronic oral cariprazine administration produced a significant, dose-dependent decrease (45%, 59%, and 66% for 0.1, 0.3, and 1 mg/kg, respectively) in the number of spontaneously active VTA dopaminergic neurons (P < .01; Figure 1B ). In contrast, oral cariprazine did not significantly alter the number of spontaneously active SNc dopaminergic neurons compared with vehicle ( Figure 1B ).
| Dose-response relationship of the effects of cariprazine on firing frequency and bursting activity of VTA and SNc dopaminergic neurons
The i.v. administration of vehicle did not significantly affect firing activity when administered prior to cariprazine ( Figure 2A,B) ; the mean firing levels after vehicle injection were 96.6 ± 1.2%
and 102.2 ± 1.5% of baseline in the VTA and SNc, respectively.
Cariprazine significantly decreased the firing rate of VTA DA neurons (F (7, 56) = 55.1, P < .0001; Figure 2C ), plateauing at approximately 38% inhibition (ED 50 = 7.5 μg/kg). Similarly, cariprazine significantly suppressed the firing rate of SNc DA neurons (F (6,48) = 23.1, P < .0001; Figure 2D ); inhibition plateaued at <50% (ED 50 = 5.8 μg/kg).
Intravenous administration of cariprazine also significantly decreased the bursting activity of VTA (F (7,56) = 36.2, P < .001; Figure 2E) and SNc (F (6,18) = 31.6, P < .0001; Figure 2F ) DA neurons. Importantly, while cariprazine-induced inhibition of the mean firing rate plateaued in both regions, bursting activity was almost completely suppressed by cariprazine (VTA: 91%, ED 50 = 5.4 μg/kg; SNc: 99%, ED 50 = 3.0 μg/ kg), indicating that cariprazine preferentially affects bursting activity.
These findings suggest that cariprazine acts as a partial agonist on the firing rate and as a full agonist on bursting activity at dopamine receptors on VTA and SNc dopaminergic neurons.
| Time course of the effect of a single intravenous dose of cariprazine on the firing rate of VTA and SNc dopaminergic neurons
In the VTA, acute cariprazine administration (10 μg/kg, i.v.) inhibited dopaminergic neuron firing frequency within 2 minutes (18%), and there was no significant recovery 30 minutes after administration (27%) (F (2,10) = 15.90, P < .001; Figure 3A ). In the SNc, acute cariprazine (10 μg/kg, i.v.) suppressed the firing rate of SNc dopaminergic neurons within 2 minutes (35%), and there was a partial recovery 30 minutes after administration (18%) (F (2,14) = 8.27, P < .01; Figure 3B ). Full reversal of the inhibitory action of cariprazine on the firing rate occurred after 60 minutes in the SNc but not in the VTA (data not shown). There was no significant reversal of the inhibitory effect of cariprazine on bursting activity in either VTA or SNc DA neurons (data not shown). Cariprazine (µg/kg) (7) (7) (7) (8) *** *** *** *** *** (9) (9) (9) (9) (9) 
(9) (9) (9)
** ** ** ** ** ** ** The prior administration of the selective D 3 receptor antagonist SB 277011A (500 μg/kg, i.v.) did not significantly alter the suppressant effect of cariprazine on firing activity ( Figure 4A ). In contrast, the selective D 2 receptor antagonist L741,626 (500 μg/kg, i.v.) significantly reduced the suppressant effect of all doses of cariprazine on the firing rate (F (2, 50) =23.745, P < .0001; Figure 4A ) of VTA dopaminergic neurons. In the SNc, the prior administration of L741,626 (500 μg/kg), but not SB 277011A (500 μg/kg), significantly influenced the inhibitory action of cariprazine on DA cell firing after cumulative i.v. administration (F (2,40) = 4.56, P < .05), an effect that reached the level of significance for the 10 μg/kg dose of cariprazine (P < .05; Figure 4B ).
| Effects of cariprazine on VTA and SNc dopaminergic neurons after PD 128,907 administration
The in vitro partial agonistic activity of cariprazine at DA D 3 receptors suggested that its effects on DA neuronal firing activity ( Figure 5C ). The administration of cariprazine (20 μg/kg, i.v.; 30 seconds) partially and significantly reversed the suppressant effect of PD 128,907 on firing activity after administration (F (1,100) = 6.43, P < .05 ; Figure 5A ; F (1,80) = 13.84, P < .01; Figure 5C ), but had no significant effect on bursting activity (data not shown). . BL: baseline; SNCD: substantia nigra, compacta part, dorsal tier; SNL: substantia nigra, lateral part; SNRDM: substantia nigra, reticular part, dorsomedial tier. *P < .05, **P < .01, ***P < .001, compared to PD 128,907 alone, using one-way ANOVA followed by FLSD post hoc test. Plotted values are means ± SEM 
| Effects
| D ISCUSS I ON
This electrophysiological study analyzed the following: (i) the in vivo effects of acute and chronic administration of cariprazine on the number of spontaneously active dopaminergic neurons in the VTA and SNc regions of the midbrain, and (ii) the electrophysiological effects of acute cariprazine on those neurons, with a special emphasis on the relative contribution of DA D 2 and D 3 receptors to these effects.
As mentioned previously, schizophrenia symptoms are suggested to be associated with a hyperactivity of mesolimbic dopaminergic pathways and a hypofunction of the dopaminergic mesocortical circuits. 34, 35 In vivo, DA neurons exhibit tonic, irregular single spike firing interrupted by bursts of spikes often with decreasing spike amplitude followed by brief periods of quiescence. 31, 36 Furthermore, it has been shown that the mean firing rate and the bursting pattern of DA neurons can be modulated independently. 37, 38 A state-dependent shift in the discharge pattern might be crucial as the burst firing of DA neurons results in a much larger synaptic DA release than single spike firing 37, 39 because positive symptoms of schizophrenia are supposed to rely on a dysregulation of phasic-that is, burst-firing. 40 As previously shown with aripiprazole or bifeprunox, 41 
| CON CLUS ION
In summary, the acute oral administration of cariprazine increased the number of spontaneously active VTA dopaminergic neurons, whereas chronic administration produced the opposite effect. Rovera have nothing to disclose.
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